From IMPERIALism to EMINENence: The Noble Rise of the Second-Generation Peripheral Drug-Eluting Stent.
作者信息
Mosarla Ramya C, Secemsky Eric A
机构信息
NYU Grossman School of Medicine, New York, NY (R.C.M.).
Harvard Medical School, Boston, MA (E.A.S.).
出版信息
Circulation. 2022 Nov 22;146(21):1577-1580. doi: 10.1161/CIRCULATIONAHA.122.062255. Epub 2022 Nov 21.
Abstract
摘要
相似文献
1
From IMPERIALism to EMINENence: The Noble Rise of the Second-Generation Peripheral Drug-Eluting Stent.从帝国主义到卓越地位：第二代外周药物洗脱支架的华丽崛起
Circulation. 2022 Nov 22;146(21):1577-1580. doi: 10.1161/CIRCULATIONAHA.122.062255. Epub 2022 Nov 21.
2
Mechanisms and Patterns of Intravascular Ultrasound In-Stent Restenosis Among Bare Metal Stents and First- and Second-Generation Drug-Eluting Stents.裸金属支架以及第一代和第二代药物洗脱支架血管内超声支架内再狭窄的机制与模式
Am J Cardiol. 2015 Nov 1;116(9):1351-7. doi: 10.1016/j.amjcard.2015.07.058. Epub 2015 Aug 14.
3
3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.3 年 RIBS IV 临床试验临床随访：药物洗脱球囊与依维莫司洗脱支架治疗药物洗脱支架治疗后冠状动脉支架内再狭窄患者的前瞻性随机研究。
JACC Cardiovasc Interv. 2018 May 28;11(10):981-991. doi: 10.1016/j.jcin.2018.02.037.
4
Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.载药支架与药物球囊治疗金属裸支架内再狭窄的长期疗效：RIBS V 临床试验 3 年随访结果。
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1246-1255. doi: 10.1016/j.jcin.2016.03.037. Epub 2016 Jun 20.
5
Restenosis in a Bare-Metal Stent: Drug-Eluting Balloon or Drug-Eluting Stent?裸金属支架再狭窄：药物洗脱球囊还是药物洗脱支架？
Circ Cardiovasc Interv. 2016 Apr;9(4):e003829. doi: 10.1161/CIRCINTERVENTIONS.116.003829.
6
Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.依维莫司洗脱支架用于裸金属和药物洗脱支架内再狭窄患者：RIBS IV和V试验患者水平汇总分析结果
Circ Cardiovasc Interv. 2016 Jul;9(7). doi: 10.1161/CIRCINTERVENTIONS.115.003479.
7
Multivariable prediction model to estimate the probability of restenosis at proximal edge after 2nd-generation drug-eluting-stent implantation: development and internal validation using a quantitative coronary angiography from the post-marketing surveillance studies of everolimus-eluting stent in Japan.第二代药物洗脱支架植入后近端边缘再狭窄概率的多变量预测模型：来自日本依维莫司洗脱支架上市后监测研究的定量冠状动脉造影的开发和内部验证。
Cardiovasc Interv Ther. 2021 Apr;36(2):190-197. doi: 10.1007/s12928-020-00666-2. Epub 2020 Apr 18.
8
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V).冠状动脉疾病中的新一代药物洗脱支架：聚焦依维莫司洗脱支架（Xience V）。
Vasc Health Risk Manag. 2008;4(1):31-8. doi: 10.2147/vhrm.2008.04.01.31.
9
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.比较佐他莫司洗脱和依维莫司洗脱冠状动脉支架。
N Engl J Med. 2010 Jul 8;363(2):136-46. doi: 10.1056/NEJMoa1004130. Epub 2010 Jun 16.
10
Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study.紫杉醇洗脱球囊导管与依维莫司洗脱支架治疗冠状动脉支架内再狭窄的疗效比较：支架内再狭窄治疗研究。
Circ Cardiovasc Interv. 2016 Apr;9(4):e003316. doi: 10.1161/CIRCINTERVENTIONS.115.003316.
本文引用的文献
1
Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.药物洗脱支架与裸金属支架治疗症状性股腘动脉周围动脉疾病的疗效：EMINENT 随机试验的主要结果。
Circulation. 2022 Nov 22;146(21):1564-1576. doi: 10.1161/CIRCULATIONAHA.122.059606. Epub 2022 Oct 18.
2
1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration.股腘动脉腔内治疗中氟聚合物载药支架 1 年随访结果：再狭窄和瘤样扩张的预测因素。
JACC Cardiovasc Interv. 2022 Mar 28;15(6):630-638. doi: 10.1016/j.jcin.2022.01.019.
3
Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries.载紫杉醇无聚合物涂层支架（Zilver PTX）与载紫杉醇聚合物涂层洗脱支架（Eluvia）在健康猪股浅动脉的血管反应比较。
J Vasc Interv Radiol. 2021 Jun;32(6):792-801.e5. doi: 10.1016/j.jvir.2021.02.014. Epub 2021 Mar 4.
4
A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.载紫杉醇聚合物涂层支架与裸金属支架治疗首发股浅动脉病变的比较：BATTLE 试验
JACC Cardiovasc Interv. 2020 Feb 24;13(4):447-457. doi: 10.1016/j.jcin.2019.12.028.
5
Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.紫杉醇洗脱支架治疗最长 190mm 股浅动脉病变的疗效和安全性：Eluvia 药物洗脱支架的 IMPERIAL 长病变单臂亚研究的一年结果。
J Endovasc Ther. 2020 Apr;27(2):296-303. doi: 10.1177/1526602820901723. Epub 2020 Jan 28.
6
Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.紫杉醇涂层球囊和支架在下肢股腘动脉中的应用死亡风险：随机对照试验的系统评价和荟萃分析。
J Am Heart Assoc. 2018 Dec 18;7(24):e011245. doi: 10.1161/JAHA.118.011245.
7
A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.聚合物涂层紫杉醇洗脱支架（Eluvia）与无聚合物紫杉醇涂层支架（Zilver PTX）治疗下肢股腘动脉腔内介入治疗（IMPERIAL）：一项随机非劣效试验。
Lancet. 2018 Oct 27;392(10157):1541-1551. doi: 10.1016/S0140-6736(18)32262-1. Epub 2018 Sep 24.
9
SCAI appropriate use criteria for peripheral arterial interventions: An update.SCAI外周动脉介入治疗的合理使用标准：更新版
Catheter Cardiovasc Interv. 2017 Oct 1;90(4):E90-E110. doi: 10.1002/ccd.27141. Epub 2017 Jun 5.
10
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.紫杉醇洗脱支架治疗股腘动脉的持久临床疗效：Zilver PTX随机试验的5年结果
Circulation. 2016 Apr 12;133(15):1472-83; discussion 1483. doi: 10.1161/CIRCULATIONAHA.115.016900. Epub 2016 Mar 11.
Zotero 插件